Tumor migration/metastasis and immunosuppression are major obstacles in effective cancer therapy. Incidentally, these 2 hurdles usually coexist inside tumors, therefore making therapy significantly more complicated, as both oncogenic mechanisms must be addressed for successful therapeutic intervention. Our recent report highlights that the tumor expression of a TNF family member, CD70, is correlated with poor survival for primary gliomas. In this study, we investigated how CD70 expression by GBM affects the characteristics of tumor cells and the tumor microenvironment. We found that the ablation of CD70 in primary GBM decreased CD44 and SOX2 gene expression, and inhibited tumor migration, growth and the ability to attract monocyte-derived M2 macrophages in vitro. In the tumor microenvironment, CD70 was associated with immune cell infiltrates, such as T cells; myeloid-derived suppressor cells; and monocytes/macrophages based on the RNA-sequencing profile. The CD1631 macrophages were far more abundant than T cells were. This overwhelming level of macrophages was identified only in GBM and not in low-grade gliomas and normal brain specimens, implying their tumor association. CD70 was detected only on tumor cells, not on macrophages, and was highly correlated with CD163 gene expression in primary GBM. Additionally, the co-expression of the CD70 and CD163 genes was found to correlate with decreased survival for patients with primary GBM. Together, these data suggest that CD70 expression is involved in promoting tumor aggressiveness and immunosuppression via tumor-associated macrophage recruitment/activation. Our current efforts to target this molecule using chimeric antigen receptor T cells hold great potential for treating patients with GBM.
Glioblastomas (GBM) are highly invasive malignant brain tumors, and none of the existing treatment options are currently curative. Targeting tumors with immunotherapeutic approaches brings new hope to patients with GBM. However, very few tumor-specific targets have been identified, tested, and validated for clinical development. Tumor therapy is complicated by the involvement of both tumor aggression and the surrounding suppressive immune microenvironment. Tumors create an immunosuppressive network, which via the process of immune editing eventually prevents tumors from immune-mediated clearance. Therefore, finding a key mediator that links tumors' aggressiveness and immunosuppressive characteristics is an essential task because it can yield effective treatment outcomes for cancer patients.
CD70 is a member of the TNF family and is the only ligand found so far for CD27, 1 an important T cell costimulatory molecule. [2] [3] [4] It is a highly pleiotropic molecule as evidenced by its wide expression pattern as well as seemingly contradictory roles in immune stimulation/inhibition. It is transiently expressed on highly activated T, B, and NK cells as well as on a small subset of dendritic cells. [5] [6] [7] CD70 is also found to be expressed on many types of hematological malignancies, solid primary tumors, [8] [9] [10] [11] and metastatic tumors.
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CD70 is an important immunological regulator when it is ectopically expressed on malignant cells. Its primary role is as an immune regulator, 13 but it paradoxically has the capacity to play an immunosuppressive role inside 14 the tumor microenvironment, feeding into the immunosuppressive phenotype of many tumor types. Based on this knowledge, CD70
has been mainly identified as a diagnostic biomarker for some tumor types, 15 and the relevance and physiological consequences of CD70 expression on GBM require significant investigations.
In our recent report, we carried out the most comprehensive analysis of CD70 on gliomas to date using large sample datasets from primary and recurrent GBM patients, as well as normal brain specimens. We found CD70 expression only on glioma cells and not on normal brain tissue, and we mainly detected it in the mesenchymal subgroup of GBM as well as on IDH wild-type low-grade gliomas (LGG), the latter of which have been previously shown to be more aggressive, with limited treatment options available. 16 The most intriguing observation from our analysis was that CD70 tumor expression is an independent indicator of poor overall survival for patients with LGG and GBM, which is consistent with previous reports indicating that its expression is associated with poor prognosis in patients with other cancers. 17, 18 CD70 also serves as a tumor target. 10, 12, 19 We tested CD70-specific CAR T cells using GBM xenograft and syngeneic models and saw a profound antitumor response that translated into increased survival without observed adverse effects. 20 In this report, we focus on the mechanism of action of CD70 expression in GBM and provide evidence that CD70 expression leads to a "double jeopardy" scenario in GBM, for example, promoting tumor proliferation/migration and creating an immunosuppressive tumor microenvironment by recruiting tumor-associated macrophages (TAM). It is because of this phenomenon that targeting CD70 on tumor cells can provide a significantly robust anti-tumor response, as it eliminates 2 key driving forces of oncogenesis.
Material and Methods

Patients and samples
Specimens were obtained as paraffin-embedded tumor samples derived from patients with primary low-or high-grade gliomas who were admitted to the First Affiliated Hospital of Harbin Medical University (HMU) between January 2010 and December 2013. Healthy donors' and cancer patients' peripheral blood mononuclear cells (PBMC) were isolated from whole blood or buffy coats via density gradient centrifugation (from HMU or LifeSouth). All patients and healthy donors signed a consent form that the Committee on Human Research of the First Affiliated Hospital of HMU, and the Institutional Review Board (IRB) of the University of Florida approved. Protocols that the University of Florida IACUC approved were followed for all animal experiments.
Immunohistochemistry (IHC), immunofluorescence and fluorescence-activated cell sorting
Formalin-fixed and paraffin-embedded (FFPE) samples of resected specimens from tumors and normal tissues were used. CD70 was assessed using the mouse monoclonal anti-CD70 (Santa Cruz) antibody followed by a polyclonal goat anti-mouse/rabbit/rat IgG HRP-linker antibody conjugate and DAB1 Substrate Chromogen System (Zhongshan, Beijing, China). Other immunohistochemical staining was performed for CD3, CD4, CD8, Ki67 (Zhongshan, Beijing, China) and CD27 (Abcam). All sections were examined with a Leica DMI6000B microscope and AF6000 Modular Systems acquisition software (Leica, German). For CD70 expression evaluation, we used Image-Plus 9.1 software to measure the intensity of every image and to record the value. For counts of CD31 and CD1631 cells, as well as percent positivity of Ki67, 3 independent pathologists counted the positive cells in 10 randomized high-power fields (HPFs) of each primary glioma sample. Two counting methods were employed for CD31 T cells in this study: (1) the direct cell counts of 10 total randomized HPFs. (2) Scores: The infiltrates were scored on a scale of 0-3 based on a previous publication. 21 For the fluorescence-activated cell sorting (FACS) analysis of the macrophages, directly conjugated anti-human CD14, CD70 and CD163 (BD Biosciences, San Jose, CA) were used. FACS measurements were performed with the BD FACS Calibur, Canto II, or LSR-II Flow Cytometer (BD Biosciences) and were analyzed using FlowJo software (TreeStar, Ashland, OR).
What's new?
In this report, we demonstrate for the first time that tumor CD70 expression in GBM is involved in tumor progression by increasing the capability of tumor migration/invasion and proliferation, and by promoting the immunosuppressive tumor microenvironment via attracting tumor-associated macrophages (TAM) to the tumors. These results provide a strong rationale for the use of CAR redirected T cells in patients with CD70-positive gliomas. Tumor migration/metastasis and immunosuppression are two major and usually coexisting obstacles for effective cancer therapy. Here, the authors investigate how CD70 expression by glioblastomas (GBM) affects the characteristics of tumor cells and the tumor microenvironment. They demonstrate for the first time that tumor CD70 expression in GBM is involved in tumor progression by increasing the capability for tumor migration/invasion and proliferation, as well as in promoting the immunosuppressive tumor microenvironment by attracting tumor-associated macrophages to the tumors. These results provide a strong rationale for the use of chimeric antigen receptor-redirected T cells in patients with CD70-positive gliomas in the future.
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Over-expressing and silencing CD70 in human GBM lines Lentiviral gene constructs encoding human CD70 and controls (pD2109-EFs-CD70, pD2109-EFs-vector), or CD70 shRNA and controls (pLKO.1-puro-CD70-shRNA, pLKO.1-puro-nt-shRNA), were used as previously described. 22 Lentiviruses were transduced, respectively, into primary GBM lines derived from patients' surgically resected tumor lines 23 or commercially available cell lines. After the lentiviral transductions, a pool of resistant tumor cells was selected using puromycin (4 mg/ml). CD70 expression was determined using FACS analysis.
RNA sequencing (RNA-seq) and data analysis
Triplicate RNA isolates of separate CD70-manipulated conditions of the pGBM#3 line, that is, (1) CD70 overexpressed (Over-exp), (2) vector blank control (Blank), (3) shRNA nontarget control (NTC) and (4) CD70 shRNA were sent for RNA sequencing (Novogene, Chula Vista, CA). Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). For the data analysis, the company provided normalized data; paired-end reads were mapped to the human genome (version GRCh37/hg19) and assembled using TopHat Alignment 2 and Cufflinks Pipeline 2 from Illumina BaseSpace as the default setup. All genes and transcripts were quantified as RNA-seq by expectation-maximization (RSEM). Primary glioblastoma patients' gene expression data and matched clinical information were culled from the TCGA RNAseq v2 dataset (https://tcga-data.nci.nih.gov/docs/publications/tcga/?), and level-3 data were reorganized by using the Subio platform. A total of 151 GBM patients were separated into 2 groups by the median value of CD70 or CD163 gene expression. Tumors expressing both CD70 and CD163 > median value were grouped and defined as CD70 high CD163 high , and CD70 low C-D163 low was used for both genes < median value. KaplanMeier analysis was carried out between the CD163 groups and CD163/CD70 co-expression groups. Gene set enrichment analysis between CD70 high expressers and low expressers were performed by using GSEA software (Broad Institute). The immune metagenes of GSEA were referenced based on the published report. 24 
Real-time PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and was reverse transcribed using the iScript Reverse Transcription Supermix (Bio-Rad Laboratories). Real-time PCR was performed using the SsoAdvanced Universal Probes Supermix (Bio-Rad Laboratories) according to the manufacturer's protocols and was run on a CFX96 Touch TM Real-Time PCR Detection System (Bio-Rad Laboratories). TaqMan Gene Expression Assays (primers and probes) were purchased from Thermo Fisher Scientific; Hs01075861_m1 (CD44), Hs01053049 (SOX2), and RPL13A (Hs01578912_m1) were used for normalization; and the relative quantification of gene expression was carried out via the delta Ct methodology.
Migration and wound healing assay
Some 7 3 10 5 CD70-manipulated primary tumor cells were applied to each side of the Ibidi Culture-Insert 2 Well (Ibidi #80241) with 10% FBS DMEM (VWR 97068-075, Life Technologies 11965-118). After seeded tumor cells were settled, the inserts were removed. Imaging was captured under Olympus CKX41 (4x magnifications) for Day 0, and more images were taken on days 1 and 3.
In vitro generation of monocyte-derived M2 macrophages
Fresh PBMCs were isolated using Histopaque 1.077 from healthy donors via density gradient centrifugation, and monocytes were obtained from the PBMCs via a second round of density gradient centrifugation using a 46% Percoll working solution according to the literature. 25 In addition, monocyte A total of 500 ll of supernatant was applied to the bottom of the well. This was followed by the addition of 200 ll of 5 3 10 4 monocytederived M2 macrophages on the top of the inserts. After 24-48 hr incubation at 378C in a CO 2 incubator, the inserts were transferred to a new 24-well plate. The top of the insert membrane was washed with a cotton swab, and 1 ml of 4% paraformaldehyde was used to fix the cells for 10 min at room temperature. After washing with PBS, the membranes were stained with crystal violet for 10 min and were washed again to remove extra crystal violet. Finally, the membranes were dried and scanned underneath the membranes using a Nikon Ti-E Inverted Live Cell Imaging System.
Results
Manipulation of CD70 expression alters key tumor progressive gene expression patterns in primary GBMs and GBM cell lines
To investigate the mechanism of the action of ectopic CD70 expression in GBM, we first created lentiviral constructs that allowed us to manipulate (via overexpression or silencing) the expression levels of CD70 in GBM using primary patient tumors and commercially available lines (Fig. 1a) . We demonstrated that we can efficiently overexpress CD70 in CD70 negative lines and knock down CD70 in positive lines, pGBM3# (Fig. 1b) . Importantly, we found that CD70 silencing via shRNA in the positive lines decreased CD44 and SOX2 gene expression levels, all of which are important factors involved in glioma progression 26, 27 (Fig. 1c) . No enhancement of these markers in the CD70 negative tumor line, pGBM#1, occurred because a high preexisting baseline expression level was present (Fig. 1d) , suggesting that differential regulatory pathways are in place in CD70 negative tumors. These data provide evidence that ectopic CD70 expression in tumor cells potentiates GBM progression.
CD70 manipulation in GBM changes cell morphology, growth/survival, and migration
To further test our hypothesis that CD70 expression in GBM promotes tumor progression, we evaluated the behavior of these tumor cells, which were modified by overexpressing or silencing the gene expression of CD70. The results were quite interesting; distinct cell morphologic changes between CD70 overexpression and knockdown were observed in a CD70 positive primary GBM line (pGBM#3) in vitro. The CD70 overexpressed tumor cells, which were similar to their parental line, displayed a more mesenchymal cellular phenotype, whereas the shRNA transduced cells appeared to grow in a more spherical and aggregated manner while simultaneously decreasing (a trend but with no statistical significance) the overall cell number in vitro. Additionally, no significant difference in cell death was seen among the modified lines (Figs. 2a and 2b) . Furthermore, the CD70 overexpressed tumors showed a relatively higher capability of migration/ invasiveness than did the CD70 knocked-down cells (Figs. 2c and 2d). These results suggest that CD70 expression in GBM is directly involved in promoting aggressive tumor behaviors, such as growth and migration/invasion.
Determination of CD70-associated pathways using global gene profiling of CD70 expression in a pure tumor line and surgically resected primary GBM Next, we wanted to determine the precise oncogenic/ immunomodulatory pathway(s) that involve CD70. We Primary GBM lines (CD70 positive: pGBM#3 or CD70 negative: pGBM#1) were transduced with the lentiviral CD70 construct, CD70 shRNA/ vector, or Non-target shRNA, respectively, and the glioma-associated genes were evaluated by using RT-qPCR analysis. The RPL13A gene was used as an internal control. The data (Mean 6 SEM) were representative of 3 individual tests. The significance between 2 groups was analyzed using the paired t test ** p < 0.01, ***p < 0.001.
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were looking for the genes or gene pathways associated with CD70 that can explain the observations we found at the cellular level. We performed RNA-seq analysis on the CD70-manipulated tumor lines to investigate the global mechanism action of CD70 within tumor cell populations. The results indicated that the alteration of Cell counts (Mean 6 SEM) and the viability (propidium iodide, PI negative cells) of the cultured tumors in (a) were performed by trypan-blue and FACS analysis. The significance between 2 groups was analyzed using the unpaired t test. (c) CD70 impacts tumor migration. Wound healing assay was carried out for 3 days by seeding an equal number of tumor cells using ibidi's Culture-Inserts. The inserts were removed after the cells were settled on Day 0, and images were obtained on the indicated days. The data represent 1 of 3 independent experiments. (d) A transwell assay was also performed 2 times for these lines. The same number of CD70-manipulated cells in NSC medium were seeded in the transwell (2.5 3 10 4 / well), and medium containing FBS was loaded in the bottom of the well. Eighteen hours later, the wells were processed and quantified by counting cells in 8 HPFs/well (Mean 6 SEM). One-way ANOVA was used to determine the significant difference.
CD70 expression in GBM lines changed the tumor gene landscape (Fig. 3a) and that the knockdown of CD70 significantly decreased associated genes, such as CLU, SELL, ABCA1, THBS1, JAM3 and PLAU, and increased complement component 3 (C3) in the tumor cells (Fig.  3b) . In addition, CD44 and SOX2 were also found to be diminished (data not shown). Because tumor progression is largely supported by the tumor microenvironment, Figure 1 were analyzed by RNAsequencing, and the gene alterations after the CD70 manipulation were enriched by using hierarchical clustering (Pearson). (b) Scatter plot of data in (a) was applied between the CD70 blank vector control and the shRNA silenced samples (blue dots represent fold change, FC > 1.5, of blank/shRNA; orange dots are FC < 1.5). Top-change genes are indicated. (c) Heat map overview of top-ranked CD70 associated genes. Dataset of RNA-seq containing tissues from 155 primary GBM in TCGA database was used for the evaluation. Using CD70 mean-RSEM to stratify the genes into 2 groups: CD70 high and low (q-value <0.05, FDR < 0.05, and fold change >2, Mann-Whitney U Test). Upregulated genes along with CD70 (fold change 4, FDR < 0.01, by comparing CD70 high and low) were clustered based on molecular subtypes. The subtype information for each patient was acquired from https://cancergenome.nih.gov/ 28 . (d) CD70 expression is associated with genes in chemokine and cytokine signaling pathways. The top-ranked genes in (c) were enriched for pathways (FDR < 0.01 and fold change >2, Spearman analysis) using the PANTHER classification system: www.pantherdb. org/path way.
we next analyzed GBM tumors from surgically resected samples that contained the full repertoire of cellular components found within tumor masses, including immune infiltrates that are potentially involved in tumor progression. RNA-seq dataset culled from The Cancer Genome Atlas (TCGA) was used for this evaluation. The results indicate that CD70 is highly associated with the gene lists found in the mesenchymal subgroup (Fig. 3c ), which has been described as having relatively more immune infiltrates compared with the Proneural GBM subgroup. 28 Importantly, the gene enrichment analysis illustrated that the chemokine/cytokine receptor pathway was predominantly associated with CD70 gene expression (Fig. 3d) . Taken together, CD70 influences chemokine/ cytokine pathways in both pure tumor cell populations and whole surgically resected tumors containing immune infiltrates.
Overrepresentation of macrophages compared with T cells in primary GBM
Our group recently reported that CD70 is involved in immunosuppression and promotes tumor progression by mediating selective CD8 T cell apoptosis in GBM. 20 Next, using a gene list to define immune infiltrates, 24 we discovered that although CD70 was found to be highly associated with T cell infiltration in GBM 20 , these T cells may potentially induce tumor inhibition because a negative correlation between the percent of tumor cell proliferation marker Ki67 and CD31 T cell scores was observed (Figs. 4a-c) . However, other immunosuppressive components, such as the actions of MDSC and monocyte/macrophages, potentially impair the observed T cell effect (Table 1) . We found an overwhelming representation (3-fold more) of macrophages compared with T cells in these GBM. Additionally, compared with low-grade gliomas and normal brain specimens, the abundant macrophage LGGs (n 5 21). The significance between 2 groups was analyzed using the Mann-Whitney U test. (c) An inverse relationship between Ki67 and CD31 T cell infiltration in primary GBM. Paraffin-embedded GBM tumor samples from 22 patients were analyzed by using IHC. Average counts of 8 total randomized HPFs from each patient were evaluated using 2 continued slides for each marker, respectively. Spearman determined the correlation. (d-e) Predominant presentation of CD1631 cells in primary GBM. CD31 and CD1631 tumor infiltrating cells were evaluated by dual-color immunofluorescence staining using paraffin-embedded tumor samples derived from 10 normal brain tissues (NT), LGGs, and GBM, respectively. Average cell counts of 7 HPFs were used for the evaluation of individual normal and tumor samples. Two-way ANOVA was used for determination of significance among groups. *** p < 0.001.
infiltrations were observed only in GBM (Fig. 4d) . Collectively, CD70 may help to promote T cell tumor infiltration, and surprisingly, it may simultaneously help to trigger the immunosuppressive network that dominantly controls the tumor microenvironment.
CD70 tumor expression is associated with the incidence of CD1631 macrophages in GBM
We found that CD1631 macrophages were dramatically enriched in GBM and became the predominant immune component in GBM over T cells compared with low-grade gliomas and normal brain tissues. This finding was supported via the use of CD163 cells, as CD1631 has been considered 1 of the key markers for M2 macrophages, and TAM. 29, 30 Additionally, we also found that CD70 was associated with the chemokine production of GBM 20 . Thus, we hypothesized that a potential link exists between tumor CD70 expression and macrophage incidence or infiltration in GBM. To test our hypothesis, we first evaluated the protein expression pattern of CD70 and CD163 in GBM using paraffinembedded tumor tissues, and we found that they were expressed on tumors and macrophages, respectively. No CD70 expression was detected on the CD1631 macrophages (Fig. 5a ). To determine any possible association between CD70 and CD163, a large dataset analyzed from primary GBM samples culled from TCGA was a suitable resource for addressing this particular question. The results demonstrated that CD70 expression was indeed correlated with the macrophage gene set (Fig.5b) and CD163 gene expression (Fig. 5c) . While not reaching statistical significance, a trend was discovered regarding CD163 gene expression's correlation with overall survival (p 5 0.07, HR 5 1.4, 95% CI 5 0.95-2.11), and importantly, if tumors expressed both CD70 and CD163, clinical outcomes were significantly worsened (p 5 0.041, HR 5 1.6, 95% CI 5 0.98-2.51) (Figs. 5d and 5e ). Due to the observational nature of our study's survival data, we also included variables in each model to account for possible confounding. We included gender and age in all patient models using Cox regression and the log-rank test. Finally, to determine if a direct connection exists between CD70 tumor expression and CD1631 M2 macrophages, we performed an in vitro transwell assay using supernatants derived from CD70-manipulated GBM lines cocultured with monocyte-derived M2 macrophages from either healthy donor PBMCs or human monocyte line U937. In addition, we evaluated the attraction of these cells via the tumor supernatants (Fig. 5f) . The results indicate that the supernatants from CD70 overexpressed tumor cells attracted notably more M2 macrophages compared with the shRNA transduced cells in the donor-derived macrophages (Figs. 5g and 5h) . However, because a large variation was found when donors' monocyte-derived macrophages were used, the human-monocyte-line-U937-derived CD1631 macrophages, with the same phenotype as the donor cells, were also employed to repeat the same assay. The results confirmed a significant increase of U937-derived cell migration toward a CD70 overexpressed supernatant compared with its silenced counterpart (Fig. 5i) . Taken together, these data suggest that CD70 is directly involved in promoting the predominant infiltration of M2 or TAM in GBM.
Discussion
We are finally beginning to understand how to successfully harness cancer immunotherapeutic approaches for patients with gliomas because the treatment options for these deadly tumors are dismal and have not progressed significantly. Despite decades of study, a poor understanding exists of the underlying factors responsible for the decreased efficacy in the induction of antitumor immunity for patients with GBM. Current evidence indicates that tumor-specific T cell dysfunction has been found to be initiated in the very early stages of tumor development, 31 suggesting that finding tumor-produced factors associated with immunosuppression is a critical task in the development of successful immunotherapeutic interventions. One of our recent studies investigated a TNF family member, CD70, which was ectopically overexpressed on IDH wild-type LGG and in mesenchymal subgroup GBM, and it was correlated with poor patients' survival. Further study suggested that CD70 can selectively promote CD81 T cell death and that targeting this molecule using CAR T cells induces a profound antitumor response in preclinical models 20 . Therefore, in this report, we focused on how CD70 tumor expression influences tumor cell characteristics and consequently impacts suppressive immune components or populations, in particular, macrophages in tumor samples derived from primary GBM patients.
We first observed that the downregulation of the CD70 gene in primary GBM can result in a decrease in genes associated with tumor epithelial-mesenchymal transition (EMT) and progression, such as CD44 and SOX2. 26, 27 These genes may be 1 of 
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Ge et al. 24 including CD163, were selected as macrophages representative genes for the gene set enrichment. 24 (c) A positive correlation between CD70 and CD163 gene expression in primary GBM. The gene expression of the 2 genes was analyzed using the Spearman correlation. (d-e) Correlation between gene expressions (CD70, CD163 or both) and patient survival. Gene expression data and matched clinical information of GBM patents were culled from TCGA RNAseq v2 dataset for the analysis in (b-e). https://tcga-data.nci.nih.gov/docs/publications/tcga/, and level-3 data were downloaded. Kaplan-Meier survival curves were plotted for the association between gene expression(s) and overall survival. The log-rank test was used to compare the groups. (f) Schematic diagram of experimental design of tumor CD70 expression influencing macrophage migration/survival. Supernatants of tumor cell culture were collected on Day 8 after the tumors were seeded and used for the macrophage migration assay. (g) In vitro generation of monocyte-derived M2 macrophages. Monocytes were isolated from donor PBMCs, or a monocyte line (U937) was used for the generation of macrophages. The macrophages were then harvested and phenotyped by FACS on Day 10. (h) Migration analysis of macrophages in the presence of CD70-manipulated tumor supernatants by transwell assay. Images were taken 48 hr after the macrophages were exposed to the tumor supernatants. The images represent 1 of 4 individual experiments using donor monocyte-derived macrophages. (i) The experiment described in (h) was also reproduced using human-monocyte-line-U937-derived CD1631 macrophages. The cell counts (Mean 6 SEM) were the mean values of the migrated cells from 8 HPFs. The assay was repeated 2 times. One-way ANOVA was used to determine the significant differences.
the reasons for the tumor morphology changes that occur upon CD70 manipulations. These results prompted us to further evaluate the possible global genetic changes using RNA-seq after manipulating CD70 on the primary tumor samples. The analysis revealed that silencing CD70 led to the downregulation of several genes, including CLU, SELL (L-selectin), THBS1, JAM3, PLAU, CD44 and SOX2. These genes have been indicated to be involved in tumor invasion, metastases and progression in certain cancer types. [32] [33] [34] [35] [36] [37] Additionally, 1 gene was noted to be upregulated upon the knockdown of CD70, i.e. C3, which has been demonstrated to be a central mediator of radiotherapyinduced tumor-specific immunity. 38 The results from functional analysis were consistent with the finding that the knockdown of CD70 reduced tumor migration/invasion in vitro, suggesting that CD70 in GBM plays an important role in tumor aggressiveness/progression. Together, these results are in line with our reported finding that CD70 is involved in promoting tumor progression and is associated with poor patient survival.
This study and our previous report revealed that the chemokine productions by the tumor cells were the key characteristics of CD70-expressing tumors. These chemokines, such as IL-8, CCL2, and could be critical mediators in recruiting and activating the immunosuppressive cell population in the GBM tumors 20 . These data led us to evaluate the impact of CD70 tumor expression on the overall tumor immune landscape changes using surgical resected tumors containing tumor cells plus the entire tumor-associated immune infiltrates. By employing an established immune gene profiling approach, 24 the RNAseq datasets of primary GBM from TCGA were evaluated. We uncovered that CD70 expression was highly correlated with nearly all immune cell populations, such as T cell, NK cells, MDSCs, monocytes/macrophage and T regulatory cells, in primary GBM. Because gene profiling only reveals if an association exists between CD70 and immune infiltrates, we next wanted to use a macrophage marker to pinpoint the presence of these cells in tumor tissue sections and to observe their relationship with CD70-expressing tumors. We chose CD163, a marker commonly expressed on M2 macrophages, in our immunohistochemistry (IHC) analysis. Intriguingly, when infiltrating CD31 T cells and macrophages were evaluated with dual-color staining using primary GBM samples; we noted that the predominant cell population was the macrophages, not the T cells. Although a negative association was found between Ki67 frequency and CD31 T cell scores, the overrepresentation of CD1631 macrophages in GBM can potentially overcome the activation and subsequent tumor killing of the T cells. This is not truly surprising, as macrophages are particularly abundant and present in virtually all stages of the oncogenic process, which has been well documented previously. 39, 40 In the tumor microenvironment, macrophages, the so-called TAM, contribute to tumor growth. Progression was found to share similar phenotypes and functions with M2 macrophages, which express CD163 as well. 29, 30 It may not be sufficient to use CD163 alone to define TAM. However, the overwhelming presences of the CD1631 macrophages in GBM, and the lack of a presence or the minimal presence of this population in normal brain tissues and low-grade gliomas, respectively, strongly imply that the CD1631 macrophages in GBM are indeed TAM. In addition, because a recent report suggested that TAM in GBM are mainly monocyte-derived macrophages from peripheral blood rather than brain-resident microglia, 41 we call these CD1631 macrophages TAM.
To further test our hypothesis that CD70 expression is involved in promoting the TAM infiltration in GBM, we performed dualcolor fluorescence staining to first determine if the CD1631 macrophages were co-expressing CD70. The results demonstrated that no overlapping expression of CD70 and CD163 occurred on the same cells, suggesting that the CD70 and CD163 are individually representative of tumors and macrophages respectively in GBM. Importantly, we noted that tumors expressing both genes were associated with poor patient outcomes. Finally, the results from the in vitro experiments suggest that CD70 is responsible, at least in part, for the attraction of TAM.
In summary, we demonstrate that tumor CD70 expression in GBM is involved in tumor progression by increasing the capability of tumor migration/invasion and proliferation/survival, as well as by promoting the immunosuppressive tumor microenvironment via attracting TAM to the tumors. Importantly, we are currently in the developmental stages of the testing cell of CD70 specific CAR T cell therapy, as targeting this molecule has shown to have a profound antitumor effect without notable toxicity in preclinical models of GBM, thus offering great hope for patients with CD70-positive GBM in the near future.
